Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Research and development - MRTP

Sales, general and administrative

Impairment of intangible assets

Depreciation

Amortization

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

22nd Century Group

22nd Century Group, Inc. is a biotechnology company, which develops disruptive plant-based solutions the for life science, consumer product, and pharmaceutical markets. It focuses on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp or cannabis plants through genetic engineering, gene-editing, and modern plant breeding techniques. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

22nd Century Group advances VLN and GVB units towards profitability

22nd Century Group's Q4 2022 earnings call highlighted progress in VLN tobacco and GVB hemp/cannabis units, with plans for multi-state launches and cash positive operations in 2024. Despite challenges like the Grass Valley facility fire, the company remains focused on achieving profitability through revenue growth and market expansion. Key strengths include successful pilot results, volume growth, and a clear path to cash positivity for both business units.

22nd Century Group (XXII) reports strong Q1 performance and growth strategies

22nd Century Group (XXII) showcases strong performance and strategic initiatives to drive revenue growth and achieve cash positivity by 2024.
Despite challenges such as analyst inquiries and insurance impacts, the company's focus on cost efficiencies and margin improvements positions it for success.
Opportunities in revenue growth, bulk ingredient capacity expansion, and margin enhancements present promising prospects for future profitability and market growth.

22nd Century Group reports strong Q2 performance amidst operational challenges

22nd Century Group's Q2 performance showcased growth in sales but faced challenges in gross profit due to production mix shifts.
The company's proactive strategies for cost savings, brand value creation, and gross margin improvement indicate a focus on long-term sustainability.
Despite challenges like VLN rollout delays and tobacco business hurdles, opportunities in market differentiation and efficiency improvements are being pursued.

22nd Century Group pursues profitability through strategic shifts and cost management

22nd Century Group's Q4 2023 earnings call highlighted efforts to achieve profitability by reducing cash burn, focusing on VLN cigarettes for harm reduction, and exploring CMO opportunities in tobacco manufacturing. Despite challenges like decreased net sales and a negative gross profit, the company aims to reach breakeven by Q1 2025.

22nd Century Group reduces cash burn, aims for profitability by 2025

22nd Century Group's Q1 2024 performance reflects progress towards profitability, with improved financial discipline and operational efficiency.
While facing revenue challenges and legal disputes, the company's strategic initiatives and investor support position it for future growth and success.
The focus on reducing losses, strengthening the balance sheet, and expanding market presence underscores the company's commitment to long-term sustainability.

22nd Century Group reports Q2 financial turnaround and growth strategies

22nd Century Group's Q2 2024 performance reflects a notable financial turnaround and progress towards profitability.
Strategic initiatives, leadership appointments, and product strategies position the company for future growth and success.
While challenges remain in achieving cash positive operations, opportunities in market expansion and product innovation offer avenues for continued advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

22nd Century Group, Inc. is a biotechnology company, which engages in the business of tobacco harm reduction, reduced nicotine tobacco, and improvement of health and wellness through plant science. It operates through the Tobacco and Hemp/Cannabis segments. The Tobacco segment manufactures branded filtered cigars and cigarettes. The Hemp/Cannabis segment focuses on the bulk ingredient distillate or isolate. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Clever Leaves Holdings Inc

SNDL Inc.

Alan Sumler comes from the world of academia and brings that perspective to cannabis investing. Long positions and how he approaches his stock analysis.

Everyone Says Sell Your Cannabis Stocks! I See It Differently

NewLake Capital Partners, Inc.

They're not traditional cannabis pure plays, and that's a good thing.

2 Smartest Cannabis Stocks to Buy in 2022 and Beyond

The FDA's plan to reduce nicotine in cigarettes to near zero could mean big sales for this stock.

This Little-Known Tobacco Stock Is Getting a Huge Boost

Altria

The Food and Drug Administration (FDA) had planned to place a limit on nicotine levels in cigarettes and related products in 2009.

Two Tobacco Stocks That Would Be Affected By FDA Limits On Nicotine In Cigarettes

The Biden administration proposed a new limit on the amount of nicotine allowed in cigarettes.

Why 22nd Century Group Stock Soared Today

BUFFALO, N.Y., June 22, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, is now selling the first and only 95% reduced nicotine content cigarette compliant with the renewed federal policy initiative to require all cigarettes sold in the U.S. be made minimally or non-addictive.

22nd Century Group (Nasdaq: XXII) Supports Federal Proposal to Require Less Nicotine in All U.S. Cigarettes

BUFFALO, N.Y., June 16, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company), dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced the appointment of R. Hugh Kinsman as Chief Financial Officer. Kinsman is currently CFO of GVB Biopharma, which 22nd Century acquired effective May 13, 2022.

22nd Century Group (Nasdaq: XXII) Appoints R. Hugh Kinsman as CFO

BUFFALO, N.Y., May 27, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced that James A. Mish, Chief Executive Officer, and Richard Fitzgerald, Chief Financial Officer, will host meetings with investors at two upcoming investor conference events in June 2022.

22nd Century Group (Nasdaq: XXII) to Participate in LD Micro, Roth Capital Investor Meetings

Highly Regarded for His Extensive Sales and Marketing Experience in the Tobacco Industry

22nd Century Group (Nasdaq: XXII) Announces John J. Miller Joins Its Tobacco Business

BUFFALO, N.Y., May 18, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced that it has begun integration of GVB Biopharma, which it acquired on May 13, 2022. As a contract development and manufacturing organization (CDMO), GVB is a market share leader in hemp-derived active ingredients for the nutraceuticals, pharmaceutical and consumer goods industries. 22nd Century has posted a presentation, which includes an overview of GVB's business operations, the compelling strategic benefits of the acquisition, and strengths of the combined companies, on the Investors section of its website, at xxiicentury.com .

22nd Century Group (Nasdaq: XXII) Begins Integration of GVB Biopharma, Creating a Complete, Robust Hemp/Cannabis Platform

BUFFALO, N.Y., May 13, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced the acquisition of privately held GVB Biopharma. As a contract development and manufacturing organization (CDMO), GVB is believed to be one of the largest providers of hemp-derived active ingredients for the pharmaceutical and consumer goods industries worldwide based on total tonnage.

22nd Century Group (Nasdaq: XXII) Acquires GVB Biopharma, a Leading Hemp/Cannabis Company

22nd Century Group reported $9 million in revenues for Q1-2022, up 33% YoY. The company has released its VLN cigarettes in America (Chicago) and South Korea.

22nd Century Group: Record Revenues On VLN Cigarettes And Cannabis IP

Aurora Cannabis

Flora Growth Corp

GrowGeneration Corp

HEXO Corp

Innovative Industrial Properties

Jazz Pharmaceuticals

WM Technology

Scotts Miracle-Gro

Village Farms International

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.

10 Marijuana Stocks Lighting Up With a Focus on Earnings

22nd Century Group, Inc. (NASDAQ:XXII ) Q1 2022 Earnings Conference Call May 5, 2022 10:00 AM ET Company Participants Mei Kuo – Director of Communications and Investor Relations Jim Mish – Chief Executive Officer Mike Zercher – President and Chief Operating Officer Rich Fitzgerald – Chief Financial Officer Conference Call Participants Harrison Vivas – Cowen Brian Wright – Roth Capital Partners Jim McIlree – Dawson James Operator Welcome to the 22nd Century Group's First Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode and the floor will be opened for questions following management's prepared remarks, As a reminder, today's conference is being recorded.

22nd Century Group's (XXII) CEO Jim Mish on Q1 2022 Results - Earnings Call Transcript

BUFFALO, N.Y., May 05, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, today reported results for the first quarter ended March 31, 2022, and provided an update on recent business highlights. The Company will host a live audio webcast today at 10:00 a.m. ET.

22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the First Quarter 2022

BUFFALO, N.Y., April 29, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, today announced its support of FDA's plan to ban menthol in all cigarettes and that the Company expects VLN® Menthol King reduced nicotine cigarettes to be exempted from FDA's menthol ban under procedures detailed in FDA's proposed rule announced April 28, 2022.

22nd Century Group (Nasdaq: XXII) Expects VLN® Menthol King Reduced Nicotine Cigarettes To Be Exempted From FDA's Proposed Ban on Menthol Cigarettes

BUFFALO, N.Y., April 28, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, today announced that the Company has issued its annual letter to shareholders as part of 22nd Century's 2021 Annual Report. The 2021 letter to shareholders is reprinted below.

22nd Century Group (Nasdaq: XXII) Issues Annual Letter to Shareholders

BUFFALO, N.Y., April 27, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, today announced that James A. Mish, Chief Executive Officer, and Richard Fitzgerald, Chief Financial Officer, will host virtual meetings with investors at the A.G.P./Alliance Global Partners Spring Consumer Cannabis Conference on Tuesday, May 3, 2022.

22nd Century Group (Nasdaq: XXII) to Participate in A.G.P./Alliance Global Partner's Virtual Spring Consumer Cannabis Conference

Camber Energy

CTI BioPharma

Didi Global

Imperial Petroleum

Medavail Holdings Inc

UP Fintech Holding

Penny stocks with unusual options activity today. Are they on your watch list right now?

7 Top Penny Stocks To Watch With Unusual Options Activity In April 2022

BUFFALO, N.Y., April 14, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, will host a live webcast on Thursday, May 5, 2022, at 10:00 AM ET to discuss its 2022 first quarter results. 22nd Century will report the Company's first quarter 2022 results in a press release at 6:00 AM ET the same day.

22nd Century Group (Nasdaq: XXII) to Announce First Quarter 2022 Results on May 5, 2022

VLN ® cigarette s from 22nd Century Group (Nasdaq: XXII) contain 95% less nicotine than conventional cigarettes; now available in select Circle K convenience stores

First Cigarette That "Helps You Smoke Less" Launches National Pilot in Chicagoland

Further Enhances 22nd Century Group's Deep Expertise in Plant-Based Biotechnology

22nd Century (Nasdaq: XXII) Appoints Dr. Calvin Treat as Chief Scientific Officer

BUFFALO, N.Y., March 28, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), today announced that it has received notification from the Office of the Illinois Attorney General's Tobacco Enforcement Bureau that its VLN® cigarettes will be listed in the Illinois Directory of Participating Manufacturers effective April 4, 2022. Registration permits the Company to begin distributing VLN® – the first and only U.S. Food and Drug Administration (FDA)-authorized reduced nicotine content cigarette that “helps you smoke less” – as part of its Chicagoland pilot program.

FDA Authorized Reduced-Nicotine Cigarette from 22nd Century Group (Nasdaq: XXII) That ‘Helps You Smoke Less' Obtains Illinois Tobacco Product Listing

Roth Capital Partners has initiated research coverage on 22nd Century Group. Roth Capital Partners has initiated research coverage on 22nd Century Group.

22nd Century Group (Nasdaq: XXII) to Host Investor Meetings at Roth Capital Conference March 14-15

Carmines has submitted hundreds of PMTAs to the FDA and spearheaded the successful MRTPA submitted by 22nd Century Group (NASDAQ: XXII) that won an FDA marketing order in December 2021. COSTA MESA, CA / ACCESSWIRE / March 2, 2022 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium, nicotine-based, e-cigarette space, today announced the appointment of Edward Carmines, Ph.D.

News for 22nd Century Group Stock (XXII)